Zobrazeno 1 - 10
of 283
pro vyhledávání: '"Sarah Alter"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-16 (2019)
Abstract Background Immunotherapy targeting PD-1/PD-L1 fails to induce clinical responses in most patients with solid cancers. N-803, formerly ALT-803, is an IL-15 superagonist mutant and dimeric IL-15RαSushi-Fc fusion protein complex that enhances
Externí odkaz:
https://doaj.org/article/01c44dbd09c141fa93bc655b4604641d
Autor:
Hideki Furuya, Owen T. M. Chan, Ian Pagano, Chengjun Zhu, Nari Kim, Rafael Peres, Kanani Hokutan, Sarah Alter, Peter Rhode, Charles J. Rosser
Publikováno v:
Journal of Translational Medicine, Vol 17, Iss 1, Pp 1-12 (2019)
Abstract Background We set out to determine if the administration of subcutaneous (SQ) ALT-803 was non-inferior to standard intravesical BCG treatment in a carcinogen induced mouse (C57BL/6J) bladder cancer model. Methods Using this well-established
Externí odkaz:
https://doaj.org/article/fcab66ab53f545cfaf9a1ab7e8fe66a8
Autor:
Hing C. Wong, Weibo Cai, Emily K. Jeng, Jonah B. Sacha, Sarah Alter, Sixiang Shi, Kaiping Han, Ana C. Edwards, Lin Kong, Lijing You, Jinghai Wen, Xiaoyun Zhu, Bai Liu, Xiaoyue Chen, Gabriela M. Webb, Hao Hong, Wenxin Xu, Jack O. Egan, Peter R. Rhode
Supplementary methods. Supplementary Table S1. Antibodies used in immune cell characterization by flow cytometry. Supplementary Table S2. PK parameters of ALT-803 administered to cynomolgus monkeys. Supplementary Table S3. Representative clinical cha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8451633cf6638f9aa3f108b4b8b3a1d1
https://doi.org/10.1158/2326-6066.22538665.v1
https://doi.org/10.1158/2326-6066.22538665.v1
Autor:
Emily K. Jeng, Terra Noel, Sarah Alter, Bai Liu, Lin Kong, Jeffrey S. Miller, Weibo Cai, Sixiang Shi, Christopher G. England, Peter R. Rhode, Hing C. Wong, Monica Brown Jones
Publikováno v:
Cytokine. 107:105-112
ALT-803 is a fusion protein complex consisting of an interleukin (IL)-15 superagonist and a dimeric IL-15 receptor alpha sushi domain IgG1 Fc fusion protein. When administered to mice, ALT-803 is capable of inducing natural killer (NK) and CD8(+) T c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd853a67ecf3b01360e7fe0314695579
https://doi.org/10.1016/j.cyto.2017.12.003
https://doi.org/10.1016/j.cyto.2017.12.003
Publikováno v:
Journal of Immunological Sciences. 2:15-18
This mini review provides an overview and rationale for creating IL-15-based fusion protein complexes to be used as targeted immunotherapeutic agents. IL-15 stimulates proliferation and activation of CD8+ T and natural killer cells which result in au
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5052dd3d213b41d11b902b97c343f36d
https://doi.org/10.29245/2578-3009/2018/1.1111
https://doi.org/10.29245/2578-3009/2018/1.1111
Publikováno v:
Mechanisms of Ageing and Development. 162:53-62
In young adult BALB/c mice, antibodies to phosphorylcholine (PC) bearing the T15 (TEPC 15) idiotype confer protection against pneumococcal infections. In old age, even though PC reactive B cells are often increased, the proportion of T15+ antibodies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b16446b0d940a7707bd13f280d6be677
https://doi.org/10.1016/j.mad.2016.11.004
https://doi.org/10.1016/j.mad.2016.11.004
Autor:
Ana C. Edwards, Emily K. Jeng, Peter R. Rhode, Lijing You, Xiaoyue Chen, Xiaoyun Zhu, Weibo Cai, Bai Liu, Lin Kong, Wenxin Xu, Kaiping Han, Jinghai Wen, Sixiang Shi, Jack O. Egan, Jonah B. Sacha, Gabriela M. Webb, Sarah Alter, Hing C. Wong, Hao Hong
Publikováno v:
Cancer Immunology Research. 4:49-60
IL15, a potent stimulant of CD8+ T cells and natural killer (NK) cells, is a promising cancer immunotherapeutic. ALT-803 is a complex of an IL15 superagonist mutant and a dimeric IL15 receptor αSu/Fc fusion protein that was found to exhibit enhanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fee283d707074fc5e4779dc9128977f
https://doi.org/10.1158/2326-6066.cir-15-0093-t
https://doi.org/10.1158/2326-6066.cir-15-0093-t
Autor:
Bannan, Karen J.
Publikováno v:
Advertising Age. 5/30/2005, Vol. 76 Issue 22, Following p28-28. 1/3p. 1 Color Photograph.
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-16 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-16 (2019)
Background Immunotherapy targeting PD-1/PD-L1 fails to induce clinical responses in most patients with solid cancers. N-803, formerly ALT-803, is an IL-15 superagonist mutant and dimeric IL-15RαSushi-Fc fusion protein complex that enhances CD8+ T an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f78a25efeae640010c0eb76f339231dc
https://pubmed.ncbi.nlm.nih.gov/30898149
https://pubmed.ncbi.nlm.nih.gov/30898149